Technical Analysis for ESPR - Esperion Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical ESPR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | -3.43% | |
| Calm After Storm | Range Contraction | 1.23% | |
| Wide Bands | Range Expansion | 1.23% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.41% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.41% | |
| Calm After Storm | Range Contraction | 0.41% | |
| Lower Bollinger Band Walk | Weakness | 0.41% | |
| Wide Bands | Range Expansion | 0.41% | |
| Lower Bollinger Band Walk | Weakness | -0.22% | |
| Wide Bands | Range Expansion | -0.22% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 1 hour ago |
| Down 2 % | about 1 hour ago |
| Rose Above Previous Day's High | about 3 hours ago |
| 10 DMA Resistance | about 3 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/04/2021
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Lipid Cardiology Obesity Cholesterol Lipoprotein Lipids Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Niacin Atherosclerosis Lipoproteins
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Lipid Cardiology Obesity Cholesterol Lipoprotein Lipids Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Niacin Atherosclerosis Lipoproteins
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 53.73 |
| 52 Week Low | 18.01 |
| Average Volume | 642,448 |
| 200-Day Moving Average | 30.74 |
| 50-Day Moving Average | 27.29 |
| 20-Day Moving Average | 25.62 |
| 10-Day Moving Average | 23.68 |
| Average True Range | 1.67 |
| ADX | 23.57 |
| +DI | 18.26 |
| -DI | 36.37 |
| Chandelier Exit (Long, 3 ATRs ) | 23.76 |
| Chandelier Exit (Short, 3 ATRs ) | 23.03 |
| Upper Bollinger Band | 31.00 |
| Lower Bollinger Band | 20.25 |
| Percent B (%b) | 0.26 |
| BandWidth | 41.94 |
| MACD Line | -1.56 |
| MACD Signal Line | -1.16 |
| MACD Histogram | -0.4013 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.69 | ||||
| Resistance 3 (R3) | 25.46 | 24.35 | 25.24 | ||
| Resistance 2 (R2) | 24.35 | 23.67 | 24.46 | 25.09 | |
| Resistance 1 (R1) | 23.69 | 23.26 | 24.02 | 23.92 | 24.95 |
| Pivot Point | 22.58 | 22.58 | 22.75 | 22.69 | 22.58 |
| Support 1 (S1) | 21.92 | 21.90 | 22.25 | 22.15 | 21.11 |
| Support 2 (S2) | 20.81 | 21.49 | 20.92 | 20.97 | |
| Support 3 (S3) | 20.15 | 20.81 | 20.82 | ||
| Support 4 (S4) | 20.38 |
